Merck's big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As Reynald Castañeda, Kyle LaHucik and Lei Lei Wu bring us the latest ESMO news out of Madrid, don’t forget to sign up for our virtual event on Monday to get the experts’ take on where cancer research is now and where we are headed next.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.